Edmunds J W, Jayapalan S, DiMarco N M, Saboorian M H, Aukema H M
Department of Nutrition and Food Sciences and the Center for Research on Women's Health, Texas Woman's University, Denton, USA.
Am J Kidney Dis. 2001 Jan;37(1):73-78. doi: 10.1053/ajkd.2001.20590.
The growing use of creatine as a potential ergogenic aid among active individuals has raised concern regarding its effects on the kidney, particularly among those individuals with compromised renal function. The object of this study is to investigate the effects of oral creatine supplementation in an accepted animal model of renal cystic disease. Han:Sprague-Dawley (SPRD)-cy rats with cystic kidney disease were administered a creatine supplement at a loading dose of 2.0 g/kg of diet for 1 week, followed by 5 weeks during which the dose was one fifth this amount, mimicking typical human consumption on a body-weight basis. Cystic kidney disease progression was assessed by measuring kidney size and fluid content and determining cyst scores. Renal function was assessed by measuring serum urea and creatinine concentrations and creatinine clearance. Creatine supplementation resulted in greater cyst growth and worsened renal function in the Han:SPRD-cy rat, evidenced by greater kidney weights (2.87 +/- 0.08 versus 2.61 +/- 0.09 g/100 g of body weight; P: = 0.0365), renal fluid contents (89.22 +/- 0.41 versus 87.38 +/- 0.48 g/100 g of kidney weight; P: = 0.0057), cyst scores (0.49 +/- 0.02 versus 0.40 +/- 0.03; P: = 0.0167) and serum urea concentrations (23.96 +/- 0.92 versus 20.65 +/- 1.06 mmol/L; P: = 0.0230), and lower creatinine clearances (0.125 +/- 0.098 versus 0.162 +/- 0.011 mL/min/100 g of body weight; P: = 0.0159). These results indicate that creatine supplements may exacerbate disease progression in an animal model of cystic renal disease. Although systematic research of the effects of creatine supplementation in humans with compromised renal function is awaited, it follows that creatine should be used with particular caution in individuals with or at risk for renal disease.
在活跃人群中,越来越多的人将肌酸作为一种潜在的增强体能的辅助剂,这引发了人们对其对肾脏影响的担忧,尤其是在那些肾功能受损的人群中。本研究的目的是在一种公认的肾囊性疾病动物模型中研究口服补充肌酸的影响。患有多囊肾病的Han:Sprague-Dawley(SPRD)-cy大鼠,以2.0 g/kg饮食的负荷剂量给予肌酸补充剂,持续1周,随后5周剂量为该剂量的五分之一,模拟基于体重的典型人类摄入量。通过测量肾脏大小和液体含量并确定囊肿评分来评估多囊肾病的进展。通过测量血清尿素和肌酐浓度以及肌酐清除率来评估肾功能。补充肌酸导致Han:SPRD-cy大鼠的囊肿生长更大且肾功能恶化,表现为肾脏重量增加(2.87±0.08对2.61±0.09 g/100 g体重;P = 0.0365)、肾脏液体含量增加(89.22±0.41对87.38±0.48 g/100 g肾脏重量;P = 0.0057)、囊肿评分增加(0.49±0.02对0.40±0.03;P = (此处原文有误,推测应该是P = 0.0167))以及血清尿素浓度增加(23.96±0.92对20.65±1.06 mmol/L;P = 0.0230),而肌酐清除率降低(0.125±0.098对0.162±0.011 mL/min/100 g体重;P = 0.0159)。这些结果表明,在肾囊性疾病动物模型中,肌酸补充剂可能会加剧疾病进展。尽管仍有待对肾功能受损的人类补充肌酸的影响进行系统研究,但由此可见,肾病患者或有肾病风险的个体应特别谨慎使用肌酸。